Shanghai, China - on August 28, 2019, the first implantation of the self-developed VitaFlow^® Transcatheter Aortic Valve System of MicroPort Cardioflow was performed at Zhongshan Hospital affiliated to Fudan University. Prof. Ge Junbo, Academician of Chinese Academy of Sciences, Director of the Cardiology Department of Zhongshan Hospital, performed the surgery and successfully implanted the VitaFlow^® aortic valve into a 70-year-old male patient.

This patient was admitted due to repeated chest distress and palpitations. The ultrasonic examination showed: severe aortic stenosis combined with thickened and calcified aortic valve. Prof. Ge Junbo led the cardiac team for presurgical discussions and decided to perform Transcatheter Aortic Valve Replacement (TAVR). The surgery was completed successfully within one hour. Prof. Ge Junbo spoke highly of the VitaFlow^® Valve System after the surgery.

On the same day, Director Wu Yongjian of Fuwai Hospital affiliated to Chinese Academy of Medical Sciences and his team also performed two cases of TAVR surgery using the VitaFlow^® Valve System in two male patients respectively aged 87 and 84 years old. Both patients had a severe calcification of aortic valve. Prof. Wu highly praised the Alwide^® balloon.

MicroPort started its deployment in the field of interventional therapy for cardiovascular diseases and launched its self-development of the VitaFlow^® Valve System in 2010. The premarket clinical trial of this product was organized and implemented by Prof. Ge Junbo, and completed jointly by Zhongshan Hospital as the leading unit and ten other hospitals from across the country. On September 24, 2014, the first domestic clinical implantation of the VitaFlow^® Valve System was performed by Prof. Ge Junbo in an 83-year-old patient who remains very stable up to now. On July 10, 2019, the VitaFlow™ Valve System was granted the registration certificate by the National Medical Products Administration (NMPA) and was officially launched in domestic market.

Prof. Luo Qiyi, MicroPort CTO & MicroPort Cardioflow Chairman noted, “The price of the VitaFlow^® Valve System is expected to be above 30% cheaper than that of existing products in domestic market, which will dramatically reduce the overall costs for TAVR surgery and benefit more patients. Moreover, together with the self-developed Alwide^® balloon expanding catheter and Alpass^® introducer set of MicroPort Cardioflow, the VitaFlow^® Valve System has further provided a holistic treatment regimen for doctors and improved the safety and effectiveness of TAVR surgery.